Related Experiment Video
Updated: Jun 7, 2025

07:48
Assessing Therapeutic Angiogenesis in a Murine Model of Hindlimb Ischemia
Published on: June 8, 2019
8.7K
Targeting CD36 With EP 80317 Reduces Remote Inflammatory Response to Hind Limb Ischemia-Reperfusion in Mice
Hanan Elimam1,2, Jade Gauvin1, David N Huynh1
1Faculty of Pharmacy, Université de Montréal, Montréal, Québec, Canada.
Journal of Biochemical and Molecular Toxicology
|November 18, 2024
Summary
Targeting cluster of differentiation-36 (CD36) on macrophages can reduce distant lung injury after skeletal muscle ischemia-reperfusion. This approach mitigates oxidative stress and inflammation, offering a promising therapeutic strategy for related tissue damage.
Area of Science:
- Immunology
- Pathophysiology
- Pharmacology
Background:
- Ischemia-reperfusion of skeletal muscle causes oxidative stress and inflammation, leading to remote organ damage, particularly in the lungs.
- The cluster of differentiation-36 (CD36) receptor plays a key role in inflammatory pathways, acting as a scavenger receptor and Toll-like receptor coreceptor on macrophages.
- Inflammatory mediators like cytokines, chemokines, and arachidonic acid metabolites are implicated in this process.
Purpose of the Study:
- To investigate the role of CD36 signaling in remote lung inflammation following hind limb ischemia-reperfusion in a mouse model.
- To evaluate the therapeutic potential of a CD36 modulator, EP 80317, in mitigating lung injury.
Main Methods:
- Hind limb ischemia was induced in mice, followed by reperfusion, with subsequent analysis of blood and lung tissue.
- Measurements included reactive oxygen species, inflammatory mediators, gene expression, leukocyte recruitment, NLRP3 inflammasome activation, NF-κB signaling, and arachidonic acid metabolite release.
- The CD36 modulator EP 80317 was administered to assess its effect on inflammation and lung injury.
Main Results:
- Ischemia-reperfusion led to increased oxidative stress, inflammation, and lung injury.
- CD36 signaling was involved in leukocyte recruitment, NLRP3 inflammasome activation, NF-κB activity, and inflammatory mediator release.
- Administration of EP 80317 effectively reduced pro-inflammatory signaling and transcriptional activity, thereby abating lung injury.
Conclusions:
- CD36 signaling is a critical mediator of remote lung inflammation and injury following skeletal muscle ischemia-reperfusion.
- Targeting CD36 with modulators like EP 80317 presents a promising therapeutic strategy to prevent distant organ damage.
- This study highlights the potential of CD36 as a therapeutic target for ischemia-reperfusion injury.

